Payment overview · 2025
General Payments
$753.64
36 reported records · 19 companies
Healthcare provider profile · identity verified
Robert Berke, M.D.
Allopathic & Osteopathic Physicians|General Practice · WESTFIELD, NY · NPI 1720057599
Verified facts
What the public records show
CMS Open Payments records show Robert Berke, M.D. received $753.64 in general payments during 2025 across 36 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 12.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 557 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $93.92 | 12.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $84.44 | 11.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $83.27 | 11.1% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $73.25 | 9.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.52 | 7.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.47 | 6.7% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.43 | 5.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.29 | 5.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.56 | 4.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.21 | 4.5% | 2 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $24.14 | 3.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22.43 | 3.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.15 | 2.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.31 | 2.4% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.62 | 2.3% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.07 | 2.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.61 | 2.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.00 | 2.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.95 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $753.64 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $93.92 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $73.25 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $57.67 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $52.52 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.05 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $41.43 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.29 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.56 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.56 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.21 | 2 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 145 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 138 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
145 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
34 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
557 | 74 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 634 | 173 |
| Eliquis | Apixaban | 557 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 489 | 107 |
| Lisinopril | Lisinopril | 402 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 384 | 92 |
| Furosemide | Furosemide | 374 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 316 | 98 |
| Gabapentin | Gabapentin | 291 | 77 |
| Trazodone Hcl | Trazodone Hcl | 274 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 268 | 46 |
| Potassium Chloride | Potassium Chloride | 268 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 265 | 62 |
| Sertraline Hcl | Sertraline Hcl | 259 | 43 |
| Metformin Hcl | Metformin Hcl | 250 | 60 |
| Xarelto | Rivaroxaban | 234 | 31 |
| Losartan Potassium | Losartan Potassium | 225 | 64 |
| Omeprazole | Omeprazole | 201 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 199 | 45 |
| Baclofen | Baclofen | 187 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 47 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 165 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 155 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 50 |
| Farxiga | Dapagliflozin Propanediol | 145 | 16 |
| Bumetanide | Bumetanide | 144 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 41 |
| Jardiance | Empagliflozin | 138 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 59 |
| Simvastatin | Simvastatin | 126 | 31 |
| Carvedilol | Carvedilol | 122 | 37 |
| Prednisone | Prednisone | 120 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 29 |
| Allopurinol | Allopurinol | 116 | 33 |
| Famotidine | Famotidine | 114 | 39 |
| Metformin Hcl Er | Metformin Hcl | 114 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 27 |
| Montelukast Sodium | Montelukast Sodium | 108 | 28 |
| Levetiracetam | Levetiracetam | 105 | 13 |
| Mirtazapine | Mirtazapine | 98 | 31 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 94 | 13 |
| Entresto | Sacubitril/Valsartan | 91 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 80 | 28 |
| Spironolactone | Spironolactone | 79 | 21 |
| Buspirone Hcl | Buspirone Hcl | 78 | 19 |
| Tramadol Hcl | Tramadol Hcl | 78 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 76 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 67 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | 13 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 65 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 65 | 20 |
| Topiramate | Topiramate | 64 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 12 |
| Atenolol | Atenolol | 61 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 13 |
| Ondansetron Odt | Ondansetron | 61 | 29 |
| Risperidone | Risperidone | 61 | 15 |
| Warfarin Sodium | Warfarin Sodium | 61 | 11 |
| Mupirocin | Mupirocin | 60 | 22 |
| Aripiprazole | Aripiprazole | 59 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 57 | 19 |
| Naproxen | Naproxen | 57 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 13 |
| Austedo | Deutetrabenazine | 52 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | 11 |
| Celecoxib | Celecoxib | 51 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 50 | suppressed |
| Ozempic | Semaglutide | 50 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 47 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 46 | 12 |
| Lovastatin | Lovastatin | 46 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 11 |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Nyamyc | Nystatin | 45 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | 15 |
| Meloxicam | Meloxicam | 43 | 13 |
| Enalapril Maleate | Enalapril Maleate | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 13 |
| Pregabalin | Pregabalin | 42 | 19 |
| Donepezil Hcl | Donepezil Hcl | 38 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | suppressed |
| Azithromycin | Azithromycin | 37 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 18 |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Metolazone | Metolazone | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 34 | 34 |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 34 | 20 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 18 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 31 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | 11 |
| Ramipril | Ramipril | 29 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 28 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 28 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 26 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | 13 |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Nystatin | Nystatin | 23 | 13 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 22 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 16 |
| Rybelsus | Semaglutide | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | 16 |
| Olanzapine | Olanzapine | 20 | suppressed |
| Admelog | Insulin Lispro | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 13 |
| Glimepiride | Glimepiride | 18 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 17 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Humira(Cf) Pen | Adalimumab | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $753.64 · 36 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, CAPLYTA, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, GEMTESA, JARDIANCE, KEVEYIS, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, REPATHA, Rybelsus, Sunosi, TRELEGY ELLIPTA, UNITHROID, WATCHMAN FLX, Wegovy, XHANCE, ZAVZPRET, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error